Onconetix Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
ONCO
- Investments
-
4
- Share Price
-
$3.21
- (As of Friday Closing)
Onconetix General Information
Description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Contact Information
Website
www.onconetix.comCorporate Office
- 201 East Fifth Street
- Suite 1900
- Cincinnati, OH 45202
- United States
Corporate Office
- 201 East Fifth Street
- Suite 1900
- Cincinnati, OH 45202
- United States
Onconetix Timeline
Onconetix Stock Performance
As of 13-Nov-2026, Onconetix’s stock price is $3.21. Its current market cap is $2.15M with 670K shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.21 | $3.03 | $2.91 - $1.61K | $2.15M | 670K | 406K | $3.1K |
Onconetix Financials Summary
As of 30-Jun-2026, Onconetix has a trailing 12-month revenue of $646K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 747 | 1,757 | 22,109 | 9,305 |
| Revenue | 646 | 815 | 2,524 | 58 |
| EBITDA | (9,870) | (13,266) | (57,597) | (36,707) |
| Net Income | (10,196) | (14,032) | (58,691) | (37,410) |
| Total Assets | 16,426 | 24,927 | 28,182 | 87,518 |
| Total Debt | 187 | 49 | 9,447 | 9,886 |
Onconetix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Onconetix Comparisons
Industry
Financing
Details
Onconetix Competitors (56)
One of Onconetix’s 56 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| GSK | Corporation | London, United Kingdom | ||||
| mAbxience | Corporate Backed or Acquired | Madrid, Spain | ||||
| Roche | Corporation | Basel, Switzerland |
Onconetix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Onconetix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Onconetix Investments & Acquisitions (4)
Onconetix’s most recent deal was a Merger/Acquisition with Realbotix (Other Commercial Services) for . The deal was made on 11-Feb-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Realbotix (Other Commercial Services) | 11-Feb-2026 | Merger/Acquisition | Other Hardware | ||
| ProteoMediX | 15-Dec-2023 | Merger/Acquisition | Diagnostic Equipment | ||
| Wraser Pharmaceuticals (6 FDA-Approved Drugs) | 14-Jun-2023 | Corporate Asset Purchase | Other Pharmaceuticals and Biotechnology | ||
| Veru (Entadfi Capsules Business) | 19-Apr-2023 | Merger/Acquisition | Drug Discovery |
Onconetix ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.27 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Onconetix Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| ProteoMediX | Schlieren, Switzerland |
Onconetix FAQs
-
When was Onconetix founded?
Onconetix was founded in 2018.
-
Where is Onconetix headquartered?
Onconetix is headquartered in Cincinnati, OH.
-
What is the size of Onconetix?
Onconetix has 2 total employees.
-
What industry is Onconetix in?
Onconetix’s primary industry is Drug Discovery.
-
Is Onconetix a private or public company?
Onconetix is a Public company.
-
What is Onconetix’s stock symbol?
The ticker symbol for Onconetix is ONCO.
-
What is the current stock price of Onconetix?
As of 13-Nov-2026 the stock price of Onconetix is $3.21.
-
What is the current market cap of Onconetix?
The current market capitalization of Onconetix is $2.15M.
-
What is Onconetix’s current revenue?
The trailing twelve month revenue for Onconetix is $646K.
-
Who are Onconetix’s competitors?
Novartis, Novavax, GSK, mAbxience, and Roche are some of the 56 competitors of Onconetix.
-
What is Onconetix’s annual earnings per share (EPS)?
Onconetix’s EPS for 12 months was $3.1K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
